ECHC treatment increases the expression of antiapoptotic proteins (such as p53, tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), Bcl-2, MMP-2, and MMP-9) and enhances ROS generation and CytC release from mitochondria in human non-small-cell lung cancer cells [53]. The gene discussed is TNF; the disease is non-small cell lung carcinoma.